TG Therapeutics, Inc. reported a modest Q3 beat and raised the full-year net sales guidance range for Briumvi by $7.5 million ...

TG Therapeutics' Q3 earnings missed EPS expectations despite Briumvi's revenue growth. See why TGTX stock is a Buy.

TG Therapeutics Inc (TGTX) reports over 230% year-over-year revenue growth, raises full-year guidance, and outlines future ...

Third Quarter 2024 Results Key Financial Results Revenue: US$83.9m (down 49% from ...

TG Therapeutics (NASDAQ:TGTX – Free Report) had its target price increased by HC Wainwright from $49.00 to $55.00 in a report ...

Q3 2024 Earnings Call Transcript November 4, 2024 TG Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...

TG Therapeutics ( (TGTX) ) has released its Q3 earnings. Here is a breakdown of the information TG Therapeutics presented to its investors. TG ...

On Friday, TG Therapeutics Inc common stock (TGTX) stock saw a modest uptick, ending the day at $28.81 which represents a slight increase of $0.91 or 3.26% from the prior close of $27.9. The stock ...

Analyst Mayank Mamtani of B.Riley Financial reiterated a Buy rating on TG Therapeutics (TGTX – Research Report), retaining the price ...

Third quarter 2024 U.S. BRIUMVI net revenue of $83.3 million Raises full year 2024 U.S. BRIUMVI net revenue target to $300 - $305 million Conference call to be held today, November 4, 2024, at 8:30 AM ...

Greetings and welcome to the TG Therapeutics third quarter conference call and webcast. At this time, all participants are in listen-only mode. If anyone should require operator assistance, please ...

TG Therapeutics develops treatments for B-cell diseases, with a primary focus on multiple sclerosis. Its lead product, Briumvi, serves as the cornerstone of its commercial success. Briumvi ...